Friday, March 06, 2020 11:17:43 PM
Trying to find bottoms
Bourbon, for me it starts with looking at a zone. and when the zone includes a magnet like the 50ma that becomes a target to watch. Right now the 50ma is at 3.60 and climbing in the coming days. The old peak at 3.70 becomes a target energy. a retest of the 3.50 low is also possible. and today's target at 3.80 is a good place to have bought. Whatever the reason why end of day surged back up to 4 dollars ,I dont know, I also dont trust it. Its possible this low at 3.82 could be the buying moment. and the 3.47/3.50 Bottom looks even more strong as a bottom.
-------------------------------------------------------------
When evaluating the top zone 6.00-6.30, I wonder if that wasnt an overbought stretch, and shows why it came down so hard and fast. Makes me want to figure a more true energetic peak that frames the rally wave measurements better. There is a shoulder zone around 5.30 that I'm interested in . as a target for the next rally. a traders trimming target.
The success of the science will make AVXL a giant winner for investors. I dont want to get too cute selling tops in the coming cycles. Mostly ,I'm looking to find the best bargain lows to buy.
I think this 3.50 low might be the bottom. I was thinking 3.20 a few weeks ago but my bias is focused on the lower Bollinger at 3.40 and the 50ma at 3.60 and the 3.70 area, 3.80 is where the basic Fib target is. The downwave went a big step lower dropping from 3.80 to 3.47. A retest of 3.50 now, would have to be considered an automatic buy, but I wouldnt have the courage to drop 35K on that one target. I'm buying in small portions ,myself,being very cautious. and I wont might picking up a little more in this 3.75 area. if it comes down again.
-----------------------------------------------------------
In the next rally, the most interesting target zone I'll be watching to see how the price action behaves is when it retests the shoulder zone at 5.25 area.
-------------------------------------------------------------
For some trading fun, I'd be looking to buy 3.75 and sell a little at 5.25. but thats not advice for anyone .
-----------------------------------------------------
After wallowing down at 2.30 area bottom for so long, its been great to see a big rally back to test 6.30. but the downwave back to 3.50 looks a little ugly to me, so I'm still wanting to be cautious here. and I stick to buying small amounts . If it fell to 3.20 or lower I'll be buying a lot more.
------------------------------------------------------------
I'm not sure if the S+P downwave is hurting AVXL share price that much. The XBI is way higher than any correlation to the S+P.
Bourbon, for me it starts with looking at a zone. and when the zone includes a magnet like the 50ma that becomes a target to watch. Right now the 50ma is at 3.60 and climbing in the coming days. The old peak at 3.70 becomes a target energy. a retest of the 3.50 low is also possible. and today's target at 3.80 is a good place to have bought. Whatever the reason why end of day surged back up to 4 dollars ,I dont know, I also dont trust it. Its possible this low at 3.82 could be the buying moment. and the 3.47/3.50 Bottom looks even more strong as a bottom.
-------------------------------------------------------------
When evaluating the top zone 6.00-6.30, I wonder if that wasnt an overbought stretch, and shows why it came down so hard and fast. Makes me want to figure a more true energetic peak that frames the rally wave measurements better. There is a shoulder zone around 5.30 that I'm interested in . as a target for the next rally. a traders trimming target.
The success of the science will make AVXL a giant winner for investors. I dont want to get too cute selling tops in the coming cycles. Mostly ,I'm looking to find the best bargain lows to buy.
I think this 3.50 low might be the bottom. I was thinking 3.20 a few weeks ago but my bias is focused on the lower Bollinger at 3.40 and the 50ma at 3.60 and the 3.70 area, 3.80 is where the basic Fib target is. The downwave went a big step lower dropping from 3.80 to 3.47. A retest of 3.50 now, would have to be considered an automatic buy, but I wouldnt have the courage to drop 35K on that one target. I'm buying in small portions ,myself,being very cautious. and I wont might picking up a little more in this 3.75 area. if it comes down again.
-----------------------------------------------------------
In the next rally, the most interesting target zone I'll be watching to see how the price action behaves is when it retests the shoulder zone at 5.25 area.
-------------------------------------------------------------
For some trading fun, I'd be looking to buy 3.75 and sell a little at 5.25. but thats not advice for anyone .
-----------------------------------------------------
After wallowing down at 2.30 area bottom for so long, its been great to see a big rally back to test 6.30. but the downwave back to 3.50 looks a little ugly to me, so I'm still wanting to be cautious here. and I stick to buying small amounts . If it fell to 3.20 or lower I'll be buying a lot more.
------------------------------------------------------------
I'm not sure if the S+P downwave is hurting AVXL share price that much. The XBI is way higher than any correlation to the S+P.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
